Search Results

• • 448 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Adequacy of fine-needle aspiration specimens for human papillomavirus infection molecular testing in head and neck squamous cell carcinoma

  Authors:Ricardo Lastra, Michelle Pramick, Megan Nakashima, Gregory Weinstein, Kathleen Montone, Virginia LiVolsi, et al.From:CytoJournal (Vol. 10, Issue 1) Peer-Reviewed

  January-December 20133,259 words Report 1530LByline: Ricardo. Lastra, Michelle. Pramick, Megan. Nakashima, Gregory. Weinstein, Kathleen. Montone, Virginia. LiVolsi, Zubair. Baloch Background: Head and neck squamous cell carcinoma is often associated with human...

• Monitoring the coverage and impact of human papillomavirus vaccine--report of WHO meeting, November 2009/Surveillance de la couverture et des effets du vaccin antipapillomavirus humain--rapport d'une reunion de l'OMS, novembre 2009

  From:Weekly Epidemiological Record (Vol. 85, Issue 25)

  June 18, 20106,634 words Report 1850LWHO recommends that routine vaccination against human papillomavirus (HPV) be included in national immunization programmes provided that (i) the prevention of cervical cancer or other HPV-related diseases constitutes a...

• Human papillomavirus vaccines WHO position paper/Vaccins anti-papillomavirus humain Note d'information de l'OMS

  From:Weekly Epidemiological Record (Vol. 84, Issue 15)

  Apr. 10, 200913,035 words Report 1880LIn accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and vaccine combinations against diseases that have an...

• Perspectives for the development of human papillomavirus vaccines and immunotherapy

  Authors:Luis G Bermudez-Humaran and Philippe LangellaFrom:Expert Review of Vaccines (Vol. 9, Issue 1) Peer-Reviewed

  Jan. 20107,609 words Report 1530LAuthor(s): Luis G Bermúdez-Humarán [[dagger]] 1 , Philippe Langella 2 Keywords : bacterial vectors; cervical cancer; human papillomavirus; immunotherapy; mucosal vaccines Cervical cancer (CxCa) remains a...

• Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix[TM]]: profile report

  Authors:Susan J. Keam and Diane M. HarperFrom:BioDrugs (Vol. 22, Issue 3) Peer-Reviewed

  May-June 20082,953 words Article 3250LWorldwide, cervical cancer is the second most common cancer in women after breast cancer. [2,3] Current statistical analyses estimate that in 2002, 493 000 new cases of invasive cervical cancer were diagnosed and that...

• A sexual health prevention priority

  Authors:Stephen Peckham and Alison HannFrom:Bulletin of the World Health Organization (Vol. 86, Issue 6) Peer-Reviewed

  June 2008972 words Clinical report 1720LWittet and Tsu are right to point to the link between cervical cancer deaths and achieving the MDGs and the inequity in the burden of cervical cancer between developed and developing countries. Any programme that...

• Evaluating global health partnerships: A case study of a Gavi HPV vaccine application process in Uganda

  Authors:Carol Kamya, Jessica Shearer, Gilbert Asiimwe, Emily Carnahan, Nicole Salisbury, Peter Waiswa, et al.From:International Journal of Health Policy and Management (Vol. 6, Issue 6) Peer-Reviewed

  June 1, 20179,496 words Report 1650LAbstract Background: Global health partnerships have grown rapidly in number and scope, yet there has been less emphasis on their evaluation. Gavi, the Vaccine Alliance, is one such public-private partnership; in...

• Are the two human papillomavirus vaccines really similar? A systematic review of available evidence: efficacy of the two vaccines against HPV

  Authors:Simona Di Mario, Vittorio Basevi, Pier Luigi Lopalco, Sara Balduzzi, Roberto D'Amico, and Nicola MagriniFrom:Journal of Immunology Research (Vol. 2015) Peer-Reviewed

  Annual 20156,103 words Report 1390LBackground. When the bivalent and the quadrivalent HPV vaccines were marketed they were presented as having comparable efficacy against cervical cancer. Differences between the vaccines are HPV types included and...

• Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination

  Authors:Ellinor Ostensson, Maria Froberg, Amy Leval, Ann-Cathrin Hellstrom, Magnus Backlund, Niklas Zethraeus, et al.From:PLoS ONE (Vol. 10, Issue 9) Peer-Reviewed

  Sept. 23, 20157,481 words Report 1620LObjective Costs associated with HPV-related diseases such as cervical dysplasia, cervical cancer, and genital warts have not been evaluated in Sweden. These costs must be estimated in order to determine the potential...

• HPV Serology Testing Confirms High HPV Immunisation Coverage in England

  Authors:David Mesher, Elaine Stanford, Joanne White, Jamie Findlow, Rosalind Warrington, Sukamal Das, et al.From:PLoS ONE (Vol. 11, Issue 3) Peer-Reviewed

  Mar. 9, 20164,167 words Report 1590LBackground Reported human papillomavirus (HPV) vaccination coverage in England is high, particularly in girls offered routine immunisation at age 12 years. Serological surveillance can be used to validate reported...

• Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors

  Authors:Y. Sun, S. Peng, J. Qiu, J. Miao, B. Yang, J. Jeang, et al.From:Gene Therapy (Vol. 22, Issue 7) Peer-Reviewed

  July 20154,420 words Report 1740LTherapeutic human papillomavirus (HPV) vaccines have the potential to inhibit the progression of an established HPV infection to precancer and cancer lesions by targeting HPV oncoproteins. We have previously developed a...

• BME women want more information on HPV vaccination

  From:Nursing Standard (Vol. 24, Issue 10) Peer-Reviewed

  Nov. 11, 2009230 words Brief article Cultural barriers to vaccination against human papillomavirus (HPV) could be addressed in information tailored to women from black and minority ethnic (BME) backgrounds. Studies of HPV awareness and vaccine...

• Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium

  Authors:Lieven Annemans, Vanessa Remy, James Oyee, and Nathalie LargeronFrom:PharmacoEconomics (Vol. 27, Issue 3) Peer-Reviewed

  Mar. 20096,899 words Article Background: The introduction of a quadrivalent human papillomavirus (HPV; types 6, 11, 16, 18) vaccine is expected to significantly reduce the burden of cervical cancer, cervical intraepithelial neoplasia (CIN), genital...

• Gardasil

  From:Formulary (Vol. 44, Issue 2) Peer-Reviewed

  Feb. 200959 words Brief article Human papillomavirus (HPV) quadrivalent (types 6, 11, 16, 18) vaccine, recombinant (Gardasil, Merck) for the prevention of cervical, vulvar, and vaginal cancers caused by HPV types 16 and 18; genital warts caused by HPV...

• Human papillomavirus vaccine recombinant quadrivalent: first report of granuloma associated with aluminium adjuvant: case report

  From:Reactions Weekly (Issue 1235)

  Jan. 17, 2009396 words Brief article, Case ... [*] A 26-year-old woman developed a subcutaneous aluminium granuloma after receiving recombinant quadrivalent human papillomavirus (HPV) vaccine [dosage not stated] containing aluminium as an adjuvant. She had...

• New Data Show Cervical Cancer Vaccine Provided Significant Protection Through 3 Years

  From:Oncology (Vol. 21, Issue 7) Peer-Reviewed

  June 1, 2007309 words Brief article 1720LThe New England Journal of Medicine recently published results from two phase III studies of Merck's cervical cancer vaccine, Gardasil [quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine]. In...

• Vaccine blocks cervical cancer, genital warts

  From:Clinical Advisor (Vol. 9, Issue 9)

  Sept. 2006509 words Article 1430LProduct: Gardasil Company: Merck Pharmacologic class: Vaccine (HPV) Active ingredient: Quadrivalent human papillomavirus (HPV) types 6,11,16, and 18 vaccine; recombinant; aluminum adsorbed, suspension for IM...

• Oral cancer data support HPV shots for men

  Author:Sharon WorcesterFrom:Family Practice News (Vol. 37, Issue 18)

  Sept. 15, 2007348 words Brief article 1730LRecent data linking human papillomavirus with oropharyngeal cancers, which typically occur in men, suggest a need for stepped-up efforts to gain approval for use of the HPV vaccine in young men and adolescent boys,...

• Circulating CXCR5.sup.+CD4.sup.+ T Follicular-Like Helper Cell and Memory B Cell Responses to Human Papillomavirus Vaccines

  Authors:Ken Matsui, Joseph W. Adelsberger, Troy J. Kemp, Michael W. Baseler, Julie E. Ledgerwood, and Ligia A. PintoFrom:PLoS ONE (Vol. 10, Issue 9) Peer-Reviewed

  Sept. 2, 20159,522 words Report 1520LThrough the interaction of T follicular helper (Tfh) cells and B cells, efficacious vaccines can generate high-affinity, pathogen-neutralizing antibodies, and memory B cells. Using CXCR5, CXCR3, CCR6, CCR7, PD1, and...

• University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy

  Authors:Sara E. Crager, Ethan Guillen, and Matt PriceFrom:American Journal of Law & Medicine (Vol. 35, Issue 2-3) Peer-Reviewed

  Summer-Fall 200912,836 words Article ABSTRACT Human Papillomavirus (HPV) is a major cause of morbidity and mortality worldwide, with most of the disease burden concentrated in developing countries. Over 90 percent of cervical cancer deaths, almost all...